{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:56Z","timestamp":1793146676462,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-026-05003-7","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:00:36Z","timestamp":1768885236000},"page":"9151-9162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The safety of rituximab in pediatric nephrotic syndrome patients: a pharmacovigilance study of the FAERS database"],"prefix":"10.1007","volume":"399","author":[{"given":"Yanfeng","family":"Si","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1129-0456","authenticated-orcid":false,"given":"Yanqun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"46","key":"5003_CR1","doi-asserted-by":"publisher","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","volume":"97","author":"YH Ahn","year":"2018","unstructured":"Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, Shin JI, Cho MH, Lee JH, Park YS et al (2018) Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine (Baltimore) 97(46):e13157","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"5003_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F (2018) Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172(8):757\u2013764","journal-title":"JAMA Pediatr"},{"issue":"7","key":"5003_CR3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz K, D\u00f6tsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19(7):794\u2013797","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"5003_CR4","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bcp.13548","volume":"84","author":"A Bonanni","year":"2018","unstructured":"Bonanni A, Calatroni M, D\u2019Alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G et al (2018) Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 84(6):1238\u20131249","journal-title":"Br J Clin Pharmacol"},{"issue":"1-2","key":"5003_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2007.11.013","volume":"30","author":"EJ Boren","year":"2008","unstructured":"Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME (2008) The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 30(1\u20132):90\u201398","journal-title":"J Autoimmun"},{"key":"5003_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaut.2017.10.006","volume":"88","author":"A Boumediene","year":"2018","unstructured":"Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, Pawlak A, Audard V, Ollero M, Guigonis V et al (2018) Nephrutix: a randomized, double-blind, placebo vs rituximab-controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome. J Autoimmun 88:91\u2013102","journal-title":"J Autoimmun"},{"issue":"5","key":"5003_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00467-021-05345-9","volume":"37","author":"EY Chan","year":"2022","unstructured":"Chan EY, Ma AL, Tullus K (2022) Hypogammaglobulinaemia following rituximab therapy in childhood nephrotic syndrome. Pediatr Nephrol 37(5):927\u2013931","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"5003_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"EY Chan","year":"2020","unstructured":"Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, Yamamura T, Sinha A, Bagga A, Hogan J et al (2020) Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97(2):393\u2013401","journal-title":"Kidney Int"},{"issue":"6","key":"5003_CR9","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1681\/ASN.2021111472","volume":"33","author":"EY Chan","year":"2022","unstructured":"Chan EY, Yu ELM, Angeletti A, Arslan Z, Basu B, Boyer O, Chan CY, Colucci M, Dorval G, Dossier C et al (2022) Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol 33(6):1193\u20131207","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"5003_CR10","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","volume":"24","author":"MC Chaumais","year":"2009","unstructured":"Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Desch\u00eanes G (2009) Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 24(9):1753\u20131755","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"5003_CR11","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rav\u00e0 L, Ruggiero B, Emma F, Vivarelli M (2016) B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27(6):1811\u20131822","journal-title":"J Am Soc Nephrol"},{"key":"5003_CR12","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3389\/fimmu.2019.01653","volume":"10","author":"M Colucci","year":"2019","unstructured":"Colucci M, Carsetti R, Serafinelli J, Rocca S, Massella L, Gargiulo A, Lo Russo A, Capponi C, Cotugno N, Porzio O et al (2019) Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome. Front Immunol 10:1653","journal-title":"Front Immunol"},{"issue":"2","key":"5003_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/ncprheum0983","volume":"5","author":"SK Datta","year":"2009","unstructured":"Datta SK (2009) Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat Clin Pract Rheumatol 5(2):80\u201382","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"1","key":"5003_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4049\/jimmunol.180.1.361","volume":"180","author":"DJ DiLillo","year":"2008","unstructured":"DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, Kelsoe G, Tedder TF (2008) Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 180(1):361\u2013371","journal-title":"J Immunol"},{"issue":"5s","key":"5003_CR15","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1016\/j.kint.2024.11.007","volume":"107","author":"J Floege","year":"2025","unstructured":"Floege J, Gibson KL, Vivarelli M, Liew A, Radhakrishnan J, Rovin BH (2025) KDIGO 2025 clinical practice guideline for the management of nephrotic syndrome in children. Kidney Int 107(5s):S241\u2013s289","journal-title":"Kidney Int"},{"key":"5003_CR16","doi-asserted-by":"publisher","first-page":"726428","DOI":"10.3389\/fimmu.2021.726428","volume":"12","author":"M Fribourg","year":"2021","unstructured":"Fribourg M, Cioni M, Ghiggeri G, Cantarelli C, Leventhal JS, Budge K, Bin S, Riella LV, Colucci M, Vivarelli M et al (2021) CyTOF-enabled analysis identifies class-switched B cells as the main lymphocyte subset associated with disease relapse in children with idiopathic nephrotic syndrome. Front Immunol 12:726428","journal-title":"Front Immunol"},{"issue":"9","key":"5003_CR17","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00467-017-3746-9","volume":"33","author":"K Iijima","year":"2018","unstructured":"Iijima K, Sako M, Kamei K, Nozu K (2018) Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials. Pediatr Nephrol 33(9):1449\u20131455","journal-title":"Pediatr Nephrol"},{"issue":"9950","key":"5003_CR18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y et al (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384(9950):1273\u20131281","journal-title":"Lancet"},{"issue":"1","key":"5003_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00467-018-4166-1","volume":"35","author":"K Kamei","year":"2020","unstructured":"Kamei K, Ishikura K, Sako M, Ito S, Nozu K, Iijima K (2020) Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children. Pediatr Nephrol 35(1):17\u201324","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"5003_CR20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00467-018-3900-z","volume":"33","author":"K Kamei","year":"2018","unstructured":"Kamei K, Ogura M, Sato M, Ito S, Ishikura K (2018) Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome. Pediatr Nephrol 33(6):1013\u20131018","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"5003_CR21","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jamia\/ocv153","volume":"23","author":"TA Kass-Hout","year":"2016","unstructured":"Kass-Hout TA, Xu Z, Mohebbi M, Nelsen H, Baker A, Levine J, Johanson E, Bright RA (2016) OpenFDA: an innovative platform providing access to a wealth of FDA\u2019s publicly available data. J Am Med Inform Assoc 23(3):596\u2013600","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"5003_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s10194-024-01913-0","volume":"25","author":"WH Liu","year":"2024","unstructured":"Liu WH, Hu HM, Li C, Shi Q, Liu CH, Liu AX, Li YF, Zhang Y, Mao P, Fan BF (2024) Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database. J Headache Pain 25(1):206","journal-title":"J Headache Pain"},{"issue":"1","key":"5003_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13730-017-0297-7","volume":"7","author":"R Maeda","year":"2018","unstructured":"Maeda R, Kawasaki Y, Ohara S, Suyama K, Hosoya M (2018) Serum sickness with refractory nephrotic syndrome following treatment with rituximab. CEN Case Rep 7(1):69\u201372","journal-title":"CEN Case Rep"},{"key":"5003_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247626","author":"G Mahamat Abderraman","year":"2023","unstructured":"Mahamat Abderraman G, Djidita Hagr\u00e9 Y, Mahamat HA, Charfadine S, Amne AS, Khadidja AA, Rostaing L (2023) Idiopathic nephrotic syndrome in children in Chad: epidemiology and clinical outcomes. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12247626","journal-title":"J Clin Med"},{"issue":"12","key":"5003_CR25","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1007\/s00467-022-05475-8","volume":"37","author":"G Mathew","year":"2022","unstructured":"Mathew G, Sinha A, Ahmed A, Grewal N, Khandelwal P, Hari P, Bagga A (2022) Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial. Pediatr Nephrol 37(12):3117\u20133126","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"5003_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00467-018-4172-3","volume":"34","author":"AP Maxted","year":"2019","unstructured":"Maxted AP, Dalrymple RA, Chisholm D, McColl J, Tse Y, Christian MT, Reynolds BC (2019) Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome. Pediatr Nephrol 34(5):855\u2013863","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"5003_CR27","doi-asserted-by":"publisher","first-page":"e2036321","DOI":"10.1001\/jamanetworkopen.2020.36321","volume":"4","author":"CL McAtee","year":"2021","unstructured":"McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, Muscal E, Lotze T, Srivaths P, Forbes LR et al (2021) Association of rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw Open 4(2):e2036321","journal-title":"JAMA Netw Open"},{"key":"5003_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab347","author":"Y Noguchi","year":"2021","unstructured":"Noguchi Y, Tachi T, Teramachi H (2021) Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbab347","journal-title":"Brief Bioinform"},{"issue":"3","key":"5003_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.5114\/ceji.2017.70976","volume":"42","author":"K Popko","year":"2017","unstructured":"Popko K, G\u00f3rska E, Ku\u017ama-Mroczkowska E (2017) Effectiveness of rituximab in nephrotic syndrome treatment. Cent Eur J Immunol 42(3):313\u2013317","journal-title":"Cent Eur J Immunol"},{"issue":"9","key":"5003_CR30","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.ekir.2023.07.016","volume":"8","author":"MA Qader","year":"2023","unstructured":"Qader MA, Vivarelli M (2023) Children with steroid dependent nephrotic syndrome: rituximab or tacrolimus? It\u2019s all in the timing. Kidney Int Rep 8(9):1708\u20131710","journal-title":"Kidney Int Rep"},{"issue":"6","key":"5003_CR31","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jamapediatrics.2020.6150","volume":"175","author":"P Ravani","year":"2021","unstructured":"Ravani P, Lugani F, Drovandi S, Caridi G, Angeletti A, Ghiggeri GM (2021) Rituximab vs low-dose mycophenolate mofetil in recurrence of steroid-dependent nephrotic syndrome in children and young adults: a randomized clinical trial. JAMA Pediatr 175(6):631\u2013632","journal-title":"JAMA Pediatr"},{"issue":"6","key":"5003_CR32","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N et al (2011) Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6(6):1308\u20131315","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"5003_CR33","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M et al (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26(9):2259\u20132266","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"5003_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00467-012-2286-6","volume":"28","author":"M Sato","year":"2013","unstructured":"Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K (2013) Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol 28(1):145\u2013149","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"5003_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ndt\/gfac228","volume":"38","author":"A Sinha","year":"2023","unstructured":"Sinha A, Mathew G, Arushi A, Govindarajan S, Ghanapriya K, Grewal N, Rai K, Brijwal M, Kalluru SL, Tewari P et al (2023) Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects. Nephrol Dial Transplant 38(4):939\u2013949","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"5003_CR36","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","volume":"35","author":"A Trautmann","year":"2020","unstructured":"Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, Hui NK, Boyer O, Saleem MA, Feltran L et al (2020) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 35(8):1529\u20131561","journal-title":"Pediatr Nephrol"},{"issue":"21","key":"5003_CR37","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.4254\/wjh.v7.i21.2344","volume":"7","author":"Y Tsutsumi","year":"2015","unstructured":"Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, Teshima T (2015) Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 7(21):2344\u20132351","journal-title":"World J Hepatol"},{"issue":"12","key":"5003_CR38","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S2352-4642(18)30283-9","volume":"2","author":"K Tullus","year":"2018","unstructured":"Tullus K, Webb H, Bagga A (2018) Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health 2(12):880\u2013890","journal-title":"Lancet Child Adolesc Health"},{"issue":"10404","key":"5003_CR39","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0140-6736(23)01051-6","volume":"402","author":"M Vivarelli","year":"2023","unstructured":"Vivarelli M, Gibson K, Sinha A, Boyer O (2023) Childhood nephrotic syndrome. Lancet 402(10404):809\u2013824","journal-title":"Lancet"},{"issue":"4","key":"5003_CR40","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00467-015-3245-9","volume":"31","author":"H Webb","year":"2016","unstructured":"Webb H, Jaureguiberry G, Dufek S, Tullus K, Bockenhauer D (2016) Cyclophosphamide and rituximab in frequently relapsing\/steroid-dependent nephrotic syndrome. Pediatr Nephrol 31(4):589\u2013594","journal-title":"Pediatr Nephrol"},{"key":"5003_CR41","doi-asserted-by":"publisher","first-page":"1407709","DOI":"10.3389\/fphar.2024.1407709","volume":"15","author":"X Zhang","year":"2024","unstructured":"Zhang X, Ren X, Zhu T, Zheng W, Shen C, Lu C (2024) A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib. Front Pharmacol 15:1407709","journal-title":"Front Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05003-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05003-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05003-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:38:26Z","timestamp":1776393506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05003-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["5003"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05003-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The data used in this study are publicly available from the FAERS database, and no ethical approval was required. This study adheres to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}